Key Points – IPG Photonics has signed a binding offer to acquire Lumibird Medical for €300 million, plus a potential €50 million earn-out, in a move aimed at expanding its medical laser business. – The deal would strengthen IPG’s exposure to higher-margin medical markets,…
pecially ophthalmology, and raise advanced solutions to about 26% of total sales on 2025 pro forma results, up from 16% currently. – IPG expects the acquisition to be accretive to gross margin, EBITDA and adjusted EPS in the first year, and it plans to fund the purchase with cash on hand while keeping a strong balance sheet. – Coherent gains from the AI chip boom IPG Photonics (NASDAQ:IPGP) said it has signed a binding offer with Lumibird SA to acquire Lumibird Medical, a medical laser systems business focused primarily on ophthalmology, in a transaction the company said would expand its exposure to higher-margin medical markets. On a conference call discussing the proposed acquisition, IPG Chief Executive Officer Mark Gitin said the deal would be “an important milestone in IPG’s strategic evolution” and would add Lumibird Medical’s ophthalmology business to IPG’s existing medical laser presence in urology and dermatology. – This mid-cap tech stock just jumped 30%…and is still cheap Gitin said the acquisition would increase IPG’s advanced solutions revenue mix and create a broader medical laser platform spanning ophthalmology, urology and dermatology
Based on 2025 pro forma results, advanced solutions would represent about 26% of IPG’s total sales, up from 16% currently, with about $204 million in medical sales, he said. Deal Terms and Financial Impact IPG Senior Vice President and Chief Financial Officer Tim Mammen said the purchase price is 300 million euros, representing about 15.9 times Lumibird Medical’s 2025 adjusted EBITDA. The agreement also includes a contingent earn-out of up to 50 million euros based on financial performance in 2026 and 2027. – New Name, Coherent is a Compelling AI…